Tolterodine

# Tolterodine ## Overview - **Classification**: Muscarinic receptor antagonist (anticholinergic) - **Mechanism**: Competitively blocks muscarinic receptors (M2, M3) in the bladder, reducing detrusor muscle contraction. ## Primary Indications 1. **Overactive Bladder (OAB)** - Treatment of symptoms including urge urinary incontinence, urgency, and urinary frequency. ## Adult Dosing ### Standard Dosing **Overactive Bladder (OAB)** - **Immediate-Release (IR) Dose**: **2 mg** - **Frequency**: Twice daily (BID) - **Route**: Oral - **Maximum Dose**: **4 mg** BID (IR) **Overactive Bladder (OAB)** - **Extended-Release (ER/LA) Dose**: **2 mg** or **4 mg** - **Frequency**: Once daily (QD) - **Route**: Oral - **Maximum Dose**: **4 mg** QD (ER/LA) ### Dose Adjustments - **Renal Impairment**: - CrCl 10-30 mL/min: **1 mg BID (IR)** or **2 mg QD (ER/LA)**. - CrCl <10 mL/min: Generally avoided (not studied). - **Hepatic Impairment**: - Child-Pugh Class A or B: **1 mg BID (IR)** or **2 mg QD (ER/LA)**. - Child-Pugh Class C: Not recommended. - **Elderly Patients**: No specific adjustment based on age alone. Consider renal/hepatic function. ## Pediatric Dosing *Tolterodine is **not indicated** for pediatric patients. Its safety and efficacy have not been established in this population.* ### Neonates (0-28 days) - **Special Notes**: Not indicated. Safety and efficacy not established. ### Infants (1-12 months) - **Special Notes**: Not indicated. Safety and efficacy not established. ### Children (1-12 years) - **Special Notes**: Not indicated. Safety and efficacy not established. ### Adolescents (13-18 years) - **Special Notes**: Not indicated. Safety and efficacy not established. ## Safety Information ### Contraindications - **Absolute**: Urinary retention - **Absolute**: Gastric retention - **Absolute**: Uncontrolled narrow-angle glaucoma - **Absolute**: Hypersensitivity to tolterodine or fesoterodine ### Common Adverse Effects - **Very Common (>10%)**: Dry mouth (**23-33%**) - **Common (1-10%)**: Headache, dizziness, constipation, dyspepsia, abdominal pain, blurred vision, dry eyes. - **Serious but Rare**: Angioedema, QT prolongation, anaphylaxis, severe skin reactions. ### Key Drug Interactions - **Potent CYP2D6 Inhibitors (e.g., quinidine, fluoxetine, paroxetine)**: Reduce tolterodine dose to **1 mg BID (IR)** or **2 mg QD (ER/LA)**. Increases tolterodine exposure. - **Other Anticholinergics**: Additive anticholinergic effects (dry mouth, constipation, urinary retention). Avoid concomitant use. - **Drugs that prolong QT interval**: Increased risk of QT prolongation. Use with caution. ## Monitoring & Follow-up - **Before Treatment**: Assess baseline urinary symptoms; rule out other causes of OAB. - **During Treatment**: Monitor for efficacy (symptom reduction) and adverse effects (dry mouth, constipation, urinary retention). - **Clinical Signs**: Worsening urinary retention, significant gastrointestinal distress, severe vision changes, signs of allergic reaction. ## Clinical Pearls - 💡 **Tip 1**: ER/LA formulation offers once-daily dosing and may be associated with less dry mouth than IR. - 💡 **Tip 2**: Advise patients on strategies to manage dry mouth (sugar-free gum/candies, artificial saliva). - 💡 **Tip 3**: Counsel patients to report signs of urinary retention or severe constipation immediately. - 💡 **Tip 4**: Full therapeutic effect may take several weeks to become apparent. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.